NLS Pharmaceutics Ltd
Research NLS Pharmaceutics Ltd (NCEL) on Bullrun: market cap USD 16.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNCEL
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.28M
- Financial periodQ2 2026
Valuation Snapshot
latest market cap is USD 16.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.30M | -USD 2.77M | n/a | 2.16 | USD 2.20M | USD 355.00K | USD 7.25M |
| FY2024 | USD 0 | -USD 7.20M | -USD 1.07M | n/a | 2.43 | USD 650.00K | USD 7.73M | -USD 8.00M |
| FY2023 | USD 0 | -USD 3.33M | -USD 3.45M | n/a | 1.13 | USD 1.15M | USD 2.62M | -USD 1.20M |
| FY2022 | USD 0 | -USD 16.50M | -USD 5.86M | n/a | -33.52 | USD 8.95M | USD 2.02M | USD 111.00K |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 16.28M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.66M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 62.47M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 19.14M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.30B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.05B | n/a | n/a | n/a |
About NLS Pharmaceutics Ltd
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NLS Pharmaceutics Ltd's market cap?
NLS Pharmaceutics Ltd's market capitalization is USD 16.28M.
What does NLS Pharmaceutics Ltd do?
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes.